Follow-on Biologics Update

Over the past year, a debate over follow-on biologics (FOBs) has occurred in Washington as the 111th Congress attempts to balance incentives for biotech innovation against healthy price competition in the biologics market. This client alert discusses some of the issues—safety, physician choice, data exclusivity, patents and market factors—that Washington is grappling with as legislators negotiate a way forward.

Click the link below to read the full alert.